Pharmacokinetics and Pharmacodynamics of MK-8245 in Participants With Type 2 Diabetes (MK-8245-012)

A Placebo-Controlled Multiple Dose Study to Evaluate the Pharmacokinetics and Pharmacokinetics of MK-8245 in Subjects With Type 2 Diabetes

This study will assess the safety, tolerability, pharmacokinetics, and glucose lowering activity of MK-8245 in participants with type 2 diabetes. The primary hypothesis of the study is that after 4 weeks of treatment, MK-8245 produces a greater reduction in 24 hour weighted mean glucose (WMG) from baseline than placebo.

Inclusion Criteria:

• Subject has a diagnosis of type 2 diabetes and is being treated with diet and exercise alone, a single oral anti-hyperglycemic agent or a combination of two oral anti-hyperglycemic agents
• Subject is willing to follow a weight-maintaining diet and exercise program during the study
• Subject is a nonsmoker or is willing to limit smoking to 10 cigarettes per day while in the clinical research unit

Exclusion Criteria:

• Subject has a history of stroke, chronic seizures, or major neurological disorder
• Subject has a history of cancer, except certain skin and cervical cancers or cancer that was successfully treated 10 or more years prior to screening
• Subject has a history of type 1 diabetes
• Subject has used contact lenses within the last 6 months
• Subject has used any lipid-lowering therapy in the last 3 months, except statins, Zetia, or Vytorin
• Subject has more than 3 alcoholic beverages per day
• Subject has more than 6 servings of caffeine a day
• Subject has participated in a previous MK8245 study